Table 3.
Percent changes (Δ%) of primary outcome measures after 12 weeks of treatment among each group
| MetS+alfuzosin group 1 | MetS+placebo group 2 | Alfuzosin group 3 | Placebo group 4 | |
|---|---|---|---|---|
| Percent change of IPSS (Δ%) | −37.77%a,b,c | −9.8% | −27.89%a,c | −19.58% |
| Percent change of Qmax (Δ%) | +32.82%a,c | +2.25% | +30.10%a,c | +2.67% |
Data are presented as mean±SD
a
Statistically significant difference compared to placebo group
b
Statistically significant difference compared to alfuzosine group
c
Statistically significant difference compared to MetS+placebo group; p<0.05
MetS: metabolic syndrome; IPSS: international prostate symptom score; Qmax: maximum flow rate